Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Updated questionsto be asked at AGM by someone attending
View:
Post by DJDawg on Jun 22, 2023 12:17pm

Updated questionsto be asked at AGM by someone attending

I have organize and modified some that are duplicates.

NMIBC Trial progress
  1. How concrete are the recently referenced plans to expand the number of sites recruiting for the NMIBC study? For example, have the sites been determined? Have research applications been made? Have local PI's been identified.
  2. What is your timeline for BTD data submission?  Has it happened yet or is it waiting on some threshold that was determined by more recent conversations with the FDA?
  3. Do they have direction from FDA that they can share as to how many evaluable patients and % CR at what time points that they would need for AA application?
IV formulation for NSCLC and GBM
  1. What progress has been made towards an IND application? Is one expected this year, next year or beyond that?
Finances
  1. I would also like some input from our CFO on the short- and long-term plans with respect to funding. Is the company going to rely only on PPs?
Other
  1. What is within your definition of commercialization, and do you expect it this year?
  2. What is the status of vaccine trials? Any timeline? 
  3. Does the HCA know you exist? (I don’t know what this means – Dawg)
  4. Has the company sought any financial assistance from Health Canada to pursue the Vaccine research?
  5. What is the status with the collaboration with LI-ka shing knowledge institute.  Is the management planning to seek any financial participation from them or is it purely a contract to share the research facilities that are available with St. Mike's
Comment by BlueFranky on Jun 22, 2023 12:31pm
DJD- excellent questions. Thanks for your efforts!
Comment by Rumpl3StiltSkin on Jun 22, 2023 3:35pm
it also would be nice to know if they had any JV interest sniffing around??
Comment by N0taP00p on Jun 22, 2023 5:47pm
@DJD: The HCA question was one of mine. It was a bit cynical. Just asking if they are actively working with HCA or focused only on FDA. Thanks for compiling. 
Comment by DJDawg on Jun 22, 2023 5:49pm
what is HCA?
Comment by Donein25 on Jun 22, 2023 6:36pm
Health Canada. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250